Ebola vaccine trial targets HIV-Positive adults and teens
NCT ID NCT03031912
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an experimental Ebola vaccine (V920) in 251 HIV-infected adults and adolescents to see if it is safe and triggers an immune response. Participants received either the vaccine or a placebo, and researchers monitored side effects and antibody levels. The trial took place in Canada and Africa, with results helping to determine if the vaccine can protect people with HIV from Ebola.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
V920 (rVSVΔG-ZEBOV-GP) Ebola virus vaccine
What this could lead to
If successful, this could show that the Ebola vaccine is safe and effective for people living with HIV, expanding protection to a vulnerable group.
What could go wrong
This is a phase 2 trial with 251 participants, so results are still early. The vaccine may not produce a strong immune response in all HIV patients, and side effects like fever or joint pain are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHUM
Montreal, Quebec, H2X 0A9, Canada